Blood Disorder Therapeutics Market Size (2024 - 2029)

The Blood Disorder Therapeutics Market is anticipated to experience growth driven by the increasing prevalence of various blood disorders and heightened investment in research and development for advanced treatment options. Blood disorders, which affect the blood's functionality and include conditions related to white blood cells, red blood cells, platelets, and other components, are often caused by genetic mutations. The market's expansion is influenced by the need for effective therapies to address these conditions, which are commonly inherited and can significantly impact individuals' health.

Home Market Analysis Healthcare Research Pharmaceuticals Research Disease Specific Drugs Research Chronic Disorder Drugs Research Circulatory System Drugs Research Bleeding Disorder Testing Market Market Size

Market Size of Blood Disorder Therapeutics Industry

bleeding disorders therapeutics market size
Study Period 2019 - 2029
Base Year For Estimation 2023
Forecast Data Period 2024 - 2029
CAGR 6.20 %
Fastest Growing Market Asia Pacific
Largest Market North America

Major Players

bleeding disorders therapeutics market key players

*Disclaimer: Major Players sorted in no particular order

Blood Disorder Therapeutics Market Analysis

The Blood Disorder Therapeutics Market is expected to register a CAGR of 6.2% during the forecast period. Blood disorders are conditions that impact the blood's ability to function correctly. It includes problems with the white blood cells, red blood cells, platelets, bone marrow, spleen, lymph nodes, and the proteins which are involved in bleeding and clotting (hemostasis and thrombosis). Most of the blood disorders are caused by mutations in specific genes and can be passed down in families. According to the National Heart, Lung, and Blood Institute, Hemophilia A is the most common type of the disease in males then females about 1 in 4,000 to 1 in 5,000 males worldwide are born with Hemophilia A disorder and Hemophilia B occurs in approximately 1 in 20,000 newborn males worldwide. As per study published in the PLOS Medicine Journal, sickle cell anemia cases are expected to increase about 30 percent globally by the year 2050. Rising prevalence of various blood disorders and increasing investment in research and development for advance treatment options are the key driving factors in blood disorder therapeutics market.

Blood Disorder Therapeutics Industry Segmentation

Blood disorders are conditions that impact the blood's ability to function correctly. Most blood disorders decrease the number of platelets, proteins, nutrients or interfere with their function. Blood disorders covered under the market scope include anemia, bleeding disorders such as hemophilia, and blood cancers such as lymphoma, leukemia, and myeloma among others. Blood Disorder Therapeutics Market is segmented By Product Type, By Application and Geography.

By Product Type
Plasma Derived Factors
Recombinant Factors
Other Products
By Application
Hemoglobin Diosrders
Platelet Based Disorders
Plasma Disorders
Myeloproliferative Disorders
Genetic Hematology Disorders
Blood Cancers
Other Application
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America
Need A Different Region Or Segment?
Customize Now

Blood Disorder Therapeutics Market Size Summary

The Blood Disorder Therapeutics Market is poised for significant growth, driven by the increasing prevalence of blood disorders and advancements in treatment options. Blood disorders, which affect the functionality of blood components such as white and red blood cells, platelets, and proteins involved in bleeding and clotting, are often hereditary due to genetic mutations. The market is experiencing a surge in demand for recombinant factor concentrates, a key segment that utilizes recombinant technology to treat conditions like hemophilia. This segment is expected to maintain a substantial market share, supported by the growing need for effective treatments and the global increase in recombinant product production. The rising incidence of disorders such as hemophilia and sickle cell anemia underscores the critical need for innovative therapeutic solutions.

North America is anticipated to dominate the Blood Disorder Therapeutics Market, attributed to the high prevalence of blood disorders and heightened awareness among patients in the region. The United States, in particular, has a significant number of individuals affected by hemophilia and von Willebrand disease, with many lacking adequate treatment access. The region's well-established healthcare infrastructure and substantial investments in research and development further bolster market growth. The competitive landscape of the market is fragmented, with major players like Takeda Pharmaceutical Company Limited, Sanofi, and Novo Nordisk A/S leading the charge. These companies are pivotal in shaping the market dynamics, leveraging their expertise to address the growing demand for blood disorder therapeutics.

Explore More

Blood Disorder Therapeutics Market Size - Table of Contents

  1. 1. MARKET DYNAMICS

    1. 1.1 Market Overview

    2. 1.2 Market Drivers

      1. 1.2.1 Rising Prevalence of Various Blood Disorders

      2. 1.2.2 Increasing Investment in R&D for Advance Treatment Options

    3. 1.3 Market Restraints

      1. 1.3.1 High Cost of Treatment

      2. 1.3.2 Stringent Regulations Norms

    4. 1.4 Porter's Five Force Analysis

      1. 1.4.1 Threat of New Entrants

      2. 1.4.2 Bargaining Power of Buyers/Consumers

      3. 1.4.3 Bargaining Power of Suppliers

      4. 1.4.4 Threat of Substitute Products

      5. 1.4.5 Intensity of Competitive Rivalry

  2. 2. MARKET SEGMENTATION

    1. 2.1 By Product Type

      1. 2.1.1 Plasma Derived Factors

      2. 2.1.2 Recombinant Factors

      3. 2.1.3 Other Products

    2. 2.2 By Application

      1. 2.2.1 Hemoglobin Diosrders

      2. 2.2.2 Platelet Based Disorders

      3. 2.2.3 Plasma Disorders

      4. 2.2.4 Myeloproliferative Disorders

      5. 2.2.5 Genetic Hematology Disorders

      6. 2.2.6 Blood Cancers

      7. 2.2.7 Other Application

    3. 2.3 Geography

      1. 2.3.1 North America

        1. 2.3.1.1 United States

        2. 2.3.1.2 Canada

        3. 2.3.1.3 Mexico

      2. 2.3.2 Europe

        1. 2.3.2.1 Germany

        2. 2.3.2.2 United Kingdom

        3. 2.3.2.3 France

        4. 2.3.2.4 Italy

        5. 2.3.2.5 Spain

        6. 2.3.2.6 Rest of Europe

      3. 2.3.3 Asia-Pacific

        1. 2.3.3.1 China

        2. 2.3.3.2 Japan

        3. 2.3.3.3 India

        4. 2.3.3.4 Australia

        5. 2.3.3.5 South Korea

        6. 2.3.3.6 Rest of Asia-Pacific

      4. 2.3.4 Middle-East and Africa

        1. 2.3.4.1 GCC

        2. 2.3.4.2 South Africa

        3. 2.3.4.3 Rest of Middle-East and Africa

      5. 2.3.5 South America

        1. 2.3.5.1 Brazil

        2. 2.3.5.2 Argentina

        3. 2.3.5.3 Rest of South America

Blood Disorder Therapeutics Market Size FAQs

The Blood Disorder Therapeutics Market is projected to register a CAGR of 6.20% during the forecast period (2024-2029)

Takeda Pharmaceutical Company Limited (Shire Plc) , Sanofi, Novo Nordisk A/S, CSL Ltd and Pfizer Inc are the major companies operating in the Blood Disorder Therapeutics Market.

Bleeding Disorders Treatment Market Report Snapshots

Blood Disorder Therapeutics Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)